Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Makarevich, O. Omelyanenko, E. Amelchenko, T. Rybina (Minsk, Belarus). Interleukin-2 (IL-2) and interferon-γ(IF-γ) in idenitying severe community-acquired pneumonia (SCAP) clinical outcomes and complications. Eur Respir J 2011; 38: Suppl. 55, 1474

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers in severe community-acquired pneumonia (SCAP) prognosis, complications and outcomes Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Copeptin application in severe community-acquired pneumonia (SCAP) severity assessment and outcomes Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Impact of neutrophil function on outcomes of community-acquired pneumonia (CAP) in patients with cancer Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Acute respiratory failure (ARF) and severe sepsis (SS) in community acquired pneumonia (CAP): different outcomes? Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Legionella pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in Norway Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Incidence and etiology of early (E) and late (L) onset ventilator-associated pneumonia (VAP) in a university hospital Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006 Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP) Source: International Congress 2017 – The acute patient: the clinical point-of-view Year: 2017 Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021